B
Bruce E. Sands
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 597
Citations - 45113
Bruce E. Sands is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Ulcerative colitis & Inflammatory bowel disease. The author has an hindex of 83, co-authored 512 publications receiving 37593 citations. Previous affiliations of Bruce E. Sands include Mount Sinai Hospital & Princeton University.
Papers
More filters
Journal ArticleDOI
Infliximab for induction and maintenance therapy for ulcerative colitis.
Paul Rutgeerts,William J. Sandborn,Brian G. Feagan,Walter Reinisch,Allan Olson,Jewel Johanns,Suzanne Travers,Daniel Rachmilewitz,Stephen B. Hanauer,Gary R. Lichtenstein,Willem J.S. de Villiers,Daniel H. Present,Bruce E. Sands,Jean-Frederic Colombel +13 more
TL;DR: Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo.
Journal ArticleDOI
Infliximab for the treatment of fistulas in patients with Crohn's disease.
Daniel H. Present,Paul Rutgeerts,Stephan R. Targan,Stephen B. Hanauer,Lloyd Mayer,R. A. van Hogezand,Daniel K. Podolsky,Bruce E. Sands,T. Braakman,K. L. Dewoody,Th.F. Schaible,S. J. H. Van Deventer +11 more
TL;DR: Infliximab is an efficacious treatment for fistulas in patients with Crohn's disease and the most common adverse events for patients treated with infliximab were headache, abscess, upper respiratory tract infection, and fatigue.
Journal ArticleDOI
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
Xochitl C. Morgan,Timothy L. Tickle,Timothy L. Tickle,Harry Sokol,Harry Sokol,Dirk Gevers,Kathryn L. Devaney,Doyle V. Ward,Joshua A Reyes,Samir A. Shah,Neal Leleiko,Scott B. Snapper,Athos Bousvaros,Joshua R. Korzenik,Joshua R. Korzenik,Bruce E. Sands,Ramnik J. Xavier,Ramnik J. Xavier,Curtis Huttenhower,Curtis Huttenhower +19 more
TL;DR: The microbiome of ileal Crohn's disease was notable for increases in virulence and secretion pathways, and the first insights into community-wide microbial processes and pathways that underpin IBD pathogenesis are provided.
Journal ArticleDOI
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Brian G. Feagan,Paul Rutgeerts,Bruce E. Sands,Stephen B. Hanauer,Jean-Frederic Colombel,Jean-Frederic Colombel,William J. Sandborn,Gert Van Assche,Jeffrey Axler,Hyo-Jong Kim,Silvio Danese,I. Fox,Catherine Milch,Serap Sankoh,Tim Wyant,Jingcan Xu,Asit Parikh +16 more
TL;DR: Vedolizumab was more effective than placebo as induction and maintenance therapy for ulcerative colitis and the frequency of adverse events was similar in the vedolIZumab and placebo groups.
Journal ArticleDOI
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn,Brian G. Feagan,Paul Rutgeerts,Stephen B. Hanauer,Jean-Frederic Colombel,Jean-Frederic Colombel,Bruce E. Sands,Milan Lukas,Richard N. Fedorak,Scott D. Lee,Brian Bressler,I. Fox,Maria Rosario,Serap Sankoh,Jing Xu,Kristin Stephens,Catherine Milch,Asit Parikh +17 more
TL;DR: Vedolizumab-treated patients with active Crohn's disease were more likely than patients receiving placebo to have a remission, but not a CDAI-100 response, at week 6; patients with a response to induction therapy who continued to receive vedolIZumab (rather than switching to placebo) were morelikely to be in remission at week 52.